Antisense oligonucleotides targeting angiotensinogen: insights from animal studies

Antisense Oligonucleotides Targeting Protein

Improved targeting of miRNA with antisense oligonucleotides

MicroRNAs (miRNAs) are a class of 20-24 nt noncoding RNAs that regulate target mRNAs post-transcriptionally by binding with imperfect complementarity in the 3'-untranslated region (3'-UTR) and inhibiting translation or RNA stability. Current understanding of miRNA biology is limited, and antisense oligonucleotide (ASO) inhibition is a powerful technique for miRNA functionalization in vitro and ...

Targeting Kupffer cells with antisense oligonucleotides.

During proinflammatory reactions such as endotoxemia, ischemia-reperfusion and immune reactions, excessive amounts of cytokines and prostanoids are released resulting in liver injury. In the liver, Kupffer cells are the primary source of cytokines and prostanoids. Obliteration of Kupffer cells prevents experimentally-induced liver damage, suggesting a major role for Kupffer in the pathogenesis ...

Tritium Radiolabelled Antisense Oligonucleotides for ADME Studies

K. Webbley, S. Harris, J. Bloom, C. Henson, V. Wilson, C. Hawes, D. Price, J. Haffenden Pharmaron, Inc. Purpose Antisense Oligonucleotides (ASO), continue to elicit interest as novel therapeutic agents designed to specifically and selectively inhibit the production of various disease related gene products. For efficacy to occur, the therapeutic material must reach the site of action in quantiti...

Nanomedicine for tuberculosis: Insights from animal models

Patient noncompliance to current tuberculosis (TB) therapy owing to multidrug administration daily leads to treatment failure and emergence of multidrug resistant and extensively drug resistant TB. To avoid the daily dosing, application of nanotechnology is the only viable solution by virtue of sustained release of drugs. Other potential advantages of the system include the possibility of selec...